The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
One of the key benefits of the UK health system is that everyone has access to care. However, is care provided equally to all people? A paper by Matias et al. (2024) examines whether or not there are any inequalities in waiting times by socioeconomic status for women diagnosed with breast cancer in England and…
Healthcare association leaders and senators reacted to the dramatic developments at the CDC
A new 2025 report reveals that cyberattacks are increasingly disrupting patient care, with 72 percent of organizations affected
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
Here is a selection of recent executive hires, retirements, promotions and layoffs occurring across the healthcare industry. The post Healthcare Moves: A Monthly Summary of Hires and Layoffs appeared first on MedCity News.
Autolus Therapeutics’ Aucatzyl is now FDA approved for treating advanced cases of B-cell precursor acute lymphoblastic leukemia. While it goes after the same target as Gilead Sciences’ Tecartus, Autolus engineered its CAR T-therapy with properties that could improve safety, efficacy, and durability. The post ‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood…
The Economist reports that many life science companies are betting big on AI to help with drug development. Why? If AI can increase their likelihood new molecules become successful drugs, the cost of drug development will fall. AI-designed molecules show an 80-90% success rate in early-stage safety trials, compared with a historical average of just…
This volume shares findings from the KFF/The Washington Post Survey of Parents about exposure to and trust in children’s health content on social media, along with misleading claims following the approval of a generic version of mifepristone, reports of autism possibly being added to the Vaccine Injury Compensation Program, and patients using AI chatbots to…
Inaccurate provider data is creating a hidden crisis in healthcare by delaying care and driving up costs for both patients and health plans, according to CAQH CEO Sarah Ahmad. Her organization is working to address the issue by improving how provider data is collected and verified on the front end. The post Bad Provider Data…